Related Experiment Video
Updated: Aug 4, 2025
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
Preclinical Alzheimer's disease: how to predict who will decline next year?
Bernard J Hanseeuw1,2, Keith A Johnson2,3
1Department of Neurology, Cliniques Universitaires Saint-Luc, the Institute of Neuroscience, Université catholique de Louvain, 1200 Brussels, Belgium.
Brain Communications
|April 3, 2023
Abstract:
This scientific commentary refers to 'Medial temporal tau predicts memory decline in cognitively unimpaired elderly', by Kwan et al. (https://doi.org/10.1093/braincomms/fcac325).
Related Concept Videos
01:26Alzheimer's Disease: Overview
557
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
557
01:22Alzheimer's Disease: Treatment
232
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232